InvestSMART

SomnoMed Limited (ASX:SOM)

ALERT: Price-sensitive ASX Announcement for SOM
Current share price for SOM : $0.365 -0.105 (-22.34%)+
Announcement
Release
27 Jul 2026 6:39PM
Price at Release
$0.470
Full Release
download
Summary
SomnoMed Limited, a leader in oral appliance treatment solutions for sleep-related breathing disorders, announced an executive management update alongside its preliminary unaudited financial results for FY26. The company reported a slight revenue shortfall, citing changes in European market dynamics and currency impacts, with revenues between $114 million and $115 million, and EBITDA in the mid-range of $10 to $12 million. Key strategic efforts include a focus on European market engagement and the controlled release of Virtus™, a new therapy addressing obstructive sleep apnea and coexisting sleep bruxism. The company has outlined a FY27 outlook targeting high single-digit revenue growth.
Key Points
  • Ms. Amrita Blickstead steps down as Co-CEO; Ms. Karen Borg to take over as CEO.
  • FY26 unaudited revenue at $114-$115 million, below guidance.
  • Market dynamics in Europe and AUD appreciation affected revenue.
  • Launch of Virtus™, a therapy for OSA and sleep bruxism, in key markets.
  • Greg Knight promoted to COO, overseeing manufacturing and operations.
  • Targeting high single-digit revenue growth in FY27.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.